We found the absence or shallow mRNA levels of most ICs evaluated, including the currently clinically actionable targets PDCD1, CD274, and CTLA4. At variance, we found higher mRNA levels of CD24, CD47, CD276, and PVR genes, and when compared with non-tumor tissue, CD24 and CD276 were significantly overexpressed in the medulloblastomas. This evidence concerns the gene CTLA4 and medulloblastoma.